S
Soleno Therapeutics, Inc. (SLNO)
NCM – Real Time Price. Currency in USD
53.01
+53.01 (0.00%)
At close: May 15, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
53.01
+53.01 (0.00%)
At close: May 15, 2026, 4:00 PM EDT
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc.
| Name | Position |
|---|---|
| Dr. Anish Bhatnagar M.D. | Chairman, President & CEO |
| Dr. Manher A. Joshi M.D. | Chief Development Officer |
| Dr. Neil M. Cowen M.B.A., Ph.D. | Senior Vice President of New Product Planning |
| Mr. James H. MacKaness | Executive Officer |
| Mr. Jesse Schumaker | General Counsel |
| Mr. Kevin Norrett M.B.A., M.S. | Chief Business Officer |
| Ms. Jennifer Fulk | Chief Financial Officer |
| Ms. Kristen Yen M.S. | Senior Vice President of Global Clinical Operations and Patient Advocacy |
| Ms. Lauren Budesheim | Senior Vice President of People |
| Ms. Meredith Manning M.B.A. | Chief Commercial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-18 | POSASR | d109157dposasr.htm |
| 2026-05-07 | 10-Q | slno-20260331.htm |
| 2026-04-30 | 10-K/A | slno-20251231.htm |
| 2026-04-28 | SC 14D9/A | d149346dsc14d9a.htm |
| 2026-04-20 | SC TO-T | d140647dsctot.htm |
| 2026-04-07 | SC TO-C | d91998dsctoc.htm |
| 2026-04-07 | 8-K | d141594d8k.htm |
| 2026-04-06 | SC14D9C | d111234dsc14d9c.htm |
| 2026-04-06 | 8-K | d142985d8k.htm |
| 2026-03-16 | 8-K | d107502d8k.htm |